Key result
More ambitious treatment goals in COPD that focus on achieving disease stability and predictability have the potential to substantially improve patient quality of life and reduce healthcare burden.
Why the study?
To summarize key themes from a symposium discussing challenges of COPD, including its unpredictable nature, and whether treatment standards should be more ambitious.
A commentary highlighting the need for more ambitious treatment goals in COPD to achieve disease stability, reduce exacerbations, and improve patient quality of life.
Emphasizes COPD stability challenges in practice; leaves open optimal strategies pending prospective trials.
This article summarises key themes from a symposium held during the recent European Respiratory Society congress, which took place in Vienna, Austria, 7-11 September 2024. The symposium was sponsored by GSK and entitled 'Striving for disease stability in COPD: Giving patients more of their best days'. During the session, the speakers (MeiLan Han, Lowie Vanfleteren and Dave Singh) highlighted the specific challenges of chronic obstructive pulmonary disease (COPD), such as its unpredictable and unstable nature, with additional insights provided from patients with COPD in the form of video interviews. The faculty discussed whether treatment standards and goals should be more ambitious to provide all patients the stability and predictability they deserve and the opportunity to do more while living with COPD.
No takes yet. Share an insight, caveat, or question.
Han et al. (2024) conducted an editorial in Chronic obstructive pulmonary disease (COPD). Disease stability management was evaluated. More ambitious treatment goals in COPD that focus on achieving disease stability and predictability have the potential to substantially improve patient quality of life and reduce healthcare burden.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: